CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FiercePharma
Original article

{"a":[{"_":"AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market","$":{"href":"/pharma/abbvies-skyrizi-reaches-new-heights-it-continues-thrive-growing-psoriasis-market","hreflang":"en"}}]}

EarningsSkyriziHumiraPositive
AI Analysis

Summary

AbbVie's Skyrizi generated $5.55 billion in Q2 sales, matching Humira's single-quarter peak, demonstrating strong market performance as an IL-23 inhibitor in the growing psoriasis market.

Financial Highlights

Revenue

$5.55 billion

Importance:5/10
Sentiment:
0.80
earningscommercial performancepsoriasisIL-23 inhibitorrevenue growth
Related Companies

Read the original article

Published by FiercePharma on July 31, 2026 10:45 AM

Read Original